GI001 treatment for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a new cell therapy called GI001 for patients with B-cell lymphomas or leukemias that have come back or stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with a confirmed diagnosis of CD19-positive B-cell lymphoma or leukemia that has relapsed (come back) or is refractory (stopped responding to treatment)
- Your cancer must have failed at least one standard treatment plan, such as chemotherapy, targeted drugs, or antibody therapy
- You must have adequate organ function (heart, liver, kidneys) and blood cell counts to safely receive treatment
- You cannot have active uncontrolled infections, recent heart attack or stroke, or cancer that has spread to your brain or spinal fluid
- You must not be pregnant, nursing, or planning pregnancy during and for one year after treatment
- You must stop certain cancer treatments (steroids, chemotherapy, antibody drugs) for a set period before starting GI001
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This early-phase trial tests a new cell therapy called RS001 for people with certain B-cell blood cancers (lymphoma or leukemia) that haven't responded to other treatments. It aims to see if this personalized therapy can help when standard options have stopped working.
This trial tests a new injection, MTM-H-001, in adults whose B-cell lymphoma has returned or not responded after at least two prior treatments. The goal is to see if it can help control the cancer.
This trial tests an investigational cell therapy called B019 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The therapy targets cancer cells that have CD19 and/or CD22 on their surface, and the study aims to see if it is safe and effective.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.